Connect with us

Hi, what are you looking for?

Tech

Wegovy: Weight-loss jab approved for use in preventing heart attacks and strokes in UK

A weight-loss jab has been approved by the UK’s medicines regulator for use in preventing heart attacks and strokes in overweight or obese adults.

Wegovy, which is the brand name for the drug semaglutide, had already got the green light for weight management in those with obesity.

The Medicines and Healthcare products Regulatory Agency (MHRA) has now allowed it to be used in helping overweight or obese people cut their risk of heart problems.

Wegovy is the first weight-loss medication to be approved in the UK as a preventative method for “established cardiovascular disease”.

It can be prescribed to people who have a body mass index (BMI) score of 27 or above and have already been diagnosed with cardiovascular disease – a term which describes conditions relating to the heart or blood vessels.

Wegovy, made by Novo Nordisk, typically works by making people feel fuller and less hungry.

It does so by mimicking the GLP-1 hormone which is used in regulating blood sugar levels and enhancing insulin secretion. This reduces the amount of glucose, or sugar, produced by the liver.

By cutting the amount of sugar produced, it slows down how quickly food is digested.

Heart attack or stroke risk cut by a fifth – study

The approval comes as a new trial, involving 17,600 people, found that taking it as an injection once a week, for up to five years, can lower a person’s risk of a major cardiovascular event – such as a heart attack or stroke – by 20%.

While the National Institute for Health and Care Excellence (NICE) is still to approve the treatment’s use, Professor Sir Stephen Powis, national medical director for NHS England, is feeling positive.

He said it could “help reduce cardiovascular risks for high-risk patients, potentially preventing heart attacks and strokes, and giving more people the chance of a healthier future”.

The MHRA’s Shirley Hooper called it “an important step forward in tackling the serious health consequences of obesity”.

She also said she is assured “the appropriate regulatory standards of safety, quality and effectiveness” have been met.

There have been previous challenges around the supply of the medication, with Novo Nordisk warning earlier this year there were supply constraints, and that it would be focusing on supplying to “those with the highest ongoing need”.

However, for the NHS, the company states there is “a protected supply”, while the non-NHS supply will remain “constrained and limited for the foreseeable future”.

This post appeared first on sky.com

    You May Also Like

    Stocks

    In this episode of StockCharts TV‘s The MEM Edge, Mary Ellen reviews what’s shaping up in the broader markets after the Fed announced their rate cut...

    Tech

    Meta has lowered the minimum age to use the popular messaging platform WhatsApp. The move, which came into effect on Thursday, reduces the age...

    Tech

    Astronomers have discovered the Milky Way’s “most massive” stellar black hole yet. The newly discovered black hole is 33 times bigger than the sun...

    Business

    Stocks sold off Friday as inflation and geopolitical worries once again dented investor sentiment on Wall Street. A broad decline in major bank shares...

    Disclaimer: globalwashingtonwebinar.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 globalwashingtonwebinar.com | All Rights Reserved